NICE - MS drug not cost effective, says latest draft guidance
NICE - MS drug not cost effective, says latest draft
Published Date: December 1, 2011 12:01:00 AM EST
ENP Newswire - 01 December 2011
Release date- 30112011 - In further draft guidance published today , NICE, the healthcare guidance body, has not been able to recommend a daily capsule that could reduce relapses in some people who have a particular type of multiple sclerosis.
Based on the evidence submitted by its manufacturer, offering the drug would not be cost effective for the NHS, compared with the treatments that are already available for the condition. NICE has not yet issued guidance for the NHS.
The second appraisal consultation document provisionally does not recommend fingolimod (known commercially as Gilenya and manufactured by Novartis Pharmaceuticals UK) for highly active relapsing-remitting multiple sclerosis (RRMS); a type of the condition characterised by periods when symptoms worsen and then improve. The second draft has been published following a proposed discount from Novartis (called a Patient Access Scheme) to the price of fingolimod.
NICE's independent appraisal committee has not been convinced that offering fingolimod would be a cost effective option for the NHS, even with this discount (which Novartis has asked to be kept confidential) when compared with treatments currently offered to people with highly active RRMS, such as beta interferons.
Sir Andrew Dillon, Chief Executive of NICE said: 'It is important for people with multiple sclerosis to have access to different treatment options wherever possible; however these new treatments must represent value for money so that everyone can get the most out of the NHS. While Novartis submitted evidence that shows fingolimod can reduce relapses, our independent committee has not been convinced that it is a cost effective treatment option for the NHS, even with the proposed Patient Access Scheme.
'Our revised draft guidance has been published as part of a public consultation. We encourage healthcare professionals, people with multiple sclerosis and our other stakeholders to comment on our independent committee's provisional recommendation so that they can contribute to the development of this guidance.'
Those wishing to comment on NICE's draft recommendations have until Thursday 5 January 2012 to do so. NICE's independent committee will then meet again in February to review the comments received. NICE expects to publish its final guidance for the NHS in April 2012.
Until NICE issues final guidance, decisions on the funding of fingolimod should continue to be made locally by NHS bodies.
[Editorial queries for this story should be sent to firstname.lastname@example.org]
((Comments on this story may be sent to email@example.com))
Posted: December 2011